Nodular lymphocyte predominant hodgkin lymphoma and T cell/histiocyte rich large B cell lymphoma - Endpoints of a spectrum of one disease?

Sylvia Hartmann, Claudia Döring, Christina Jakobus, Benjamin Rengstl, Sebastian Newrzela, Thomas Tousseyn, Xavier Sagaert, Maurilio Ponzoni, Fabio Facchetti, Chris De Wolf-Peeters, Christian Steidl, Randy Gascoyne, Ralf Küppers, Martin Leo Hansmann

Research output: Contribution to journalArticle

Abstract

In contrast to the commonly indolent clinical behavior of nodular lymphocyte predominant Hodgkin lymphoma (NLPHL), T cell/histiocyte rich large B cell lymphoma (THRLBCL) is frequently diagnosed in advanced clinical stages and has a poor prognosis. Besides the different clinical presentations of these lymphoma entities, there are variants of NLPHL with considerable histopathologic overlap compared to THRLBCL. Especially THRLBCL-like NLPHL, a diffuse form of NLPHL, often presents a histopathologic pattern similar to THRLBCL, suggesting a close relationship between both lymphoma entities. To corroborate this hypothesis, we performed gene expression profiling of microdissected tumor cells of NLPHL, THRLBCL-like NLPHL and THRLBCL. In unsupervised analyses, the lymphomas did not cluster according to their entity. Moreover, even in supervised analyses, very few consistently differentially expressed transcripts were found, and for these genes the extent of differential expression was only moderate. Hence, there are no clear and consistent differences in the gene expression of the tumor cells of NLPHL, THRLBCL-like NLPHL and THRLBCL. Based on the gene expression studies, we identified BAT3/BAG6, HIGD1A, and FAT10/UBD as immunohistochemical markers expressed in the tumor cells of all three lymphomas. Characterization of the tumor microenvironment for infiltrating T cells and histiocytes revealed significant differences in the cellular composition between typical NLPHL and THRLBCL cases. However, THRLBCL-like NLPHL presented a histopathologic pattern more related to THRLBCL than NLPHL. In conclusion, NLPHL and THRLBCL may represent a spectrum of the same disease. The different clinical behavior of these lymphomas may be strongly influenced by differences in the lymphoma microenvironment, possibly related to the immune status of the patient at the timepoint of diagnosis.

Original languageEnglish
Article numbere78812
JournalPLoS One
Volume8
Issue number11
DOIs
Publication statusPublished - Nov 11 2013

Fingerprint

Hodgkin disease
histiocytes
Histiocytes
T-cells
Lymphocytes
B-Cell Lymphoma
lymphoma
endpoints
Hodgkin Disease
B-lymphocytes
lymphocytes
T-lymphocytes
Cells
T-Lymphocytes
Lymphoma
Tumors
Gene expression
gene expression
Gene Expression
Neoplasms

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Hartmann, S., Döring, C., Jakobus, C., Rengstl, B., Newrzela, S., Tousseyn, T., ... Hansmann, M. L. (2013). Nodular lymphocyte predominant hodgkin lymphoma and T cell/histiocyte rich large B cell lymphoma - Endpoints of a spectrum of one disease? PLoS One, 8(11), [e78812]. https://doi.org/10.1371/journal.pone.0078812

Nodular lymphocyte predominant hodgkin lymphoma and T cell/histiocyte rich large B cell lymphoma - Endpoints of a spectrum of one disease? / Hartmann, Sylvia; Döring, Claudia; Jakobus, Christina; Rengstl, Benjamin; Newrzela, Sebastian; Tousseyn, Thomas; Sagaert, Xavier; Ponzoni, Maurilio; Facchetti, Fabio; De Wolf-Peeters, Chris; Steidl, Christian; Gascoyne, Randy; Küppers, Ralf; Hansmann, Martin Leo.

In: PLoS One, Vol. 8, No. 11, e78812, 11.11.2013.

Research output: Contribution to journalArticle

Hartmann, S, Döring, C, Jakobus, C, Rengstl, B, Newrzela, S, Tousseyn, T, Sagaert, X, Ponzoni, M, Facchetti, F, De Wolf-Peeters, C, Steidl, C, Gascoyne, R, Küppers, R & Hansmann, ML 2013, 'Nodular lymphocyte predominant hodgkin lymphoma and T cell/histiocyte rich large B cell lymphoma - Endpoints of a spectrum of one disease?', PLoS One, vol. 8, no. 11, e78812. https://doi.org/10.1371/journal.pone.0078812
Hartmann, Sylvia ; Döring, Claudia ; Jakobus, Christina ; Rengstl, Benjamin ; Newrzela, Sebastian ; Tousseyn, Thomas ; Sagaert, Xavier ; Ponzoni, Maurilio ; Facchetti, Fabio ; De Wolf-Peeters, Chris ; Steidl, Christian ; Gascoyne, Randy ; Küppers, Ralf ; Hansmann, Martin Leo. / Nodular lymphocyte predominant hodgkin lymphoma and T cell/histiocyte rich large B cell lymphoma - Endpoints of a spectrum of one disease?. In: PLoS One. 2013 ; Vol. 8, No. 11.
@article{37cba34624334e36b8b98873af263640,
title = "Nodular lymphocyte predominant hodgkin lymphoma and T cell/histiocyte rich large B cell lymphoma - Endpoints of a spectrum of one disease?",
abstract = "In contrast to the commonly indolent clinical behavior of nodular lymphocyte predominant Hodgkin lymphoma (NLPHL), T cell/histiocyte rich large B cell lymphoma (THRLBCL) is frequently diagnosed in advanced clinical stages and has a poor prognosis. Besides the different clinical presentations of these lymphoma entities, there are variants of NLPHL with considerable histopathologic overlap compared to THRLBCL. Especially THRLBCL-like NLPHL, a diffuse form of NLPHL, often presents a histopathologic pattern similar to THRLBCL, suggesting a close relationship between both lymphoma entities. To corroborate this hypothesis, we performed gene expression profiling of microdissected tumor cells of NLPHL, THRLBCL-like NLPHL and THRLBCL. In unsupervised analyses, the lymphomas did not cluster according to their entity. Moreover, even in supervised analyses, very few consistently differentially expressed transcripts were found, and for these genes the extent of differential expression was only moderate. Hence, there are no clear and consistent differences in the gene expression of the tumor cells of NLPHL, THRLBCL-like NLPHL and THRLBCL. Based on the gene expression studies, we identified BAT3/BAG6, HIGD1A, and FAT10/UBD as immunohistochemical markers expressed in the tumor cells of all three lymphomas. Characterization of the tumor microenvironment for infiltrating T cells and histiocytes revealed significant differences in the cellular composition between typical NLPHL and THRLBCL cases. However, THRLBCL-like NLPHL presented a histopathologic pattern more related to THRLBCL than NLPHL. In conclusion, NLPHL and THRLBCL may represent a spectrum of the same disease. The different clinical behavior of these lymphomas may be strongly influenced by differences in the lymphoma microenvironment, possibly related to the immune status of the patient at the timepoint of diagnosis.",
author = "Sylvia Hartmann and Claudia D{\"o}ring and Christina Jakobus and Benjamin Rengstl and Sebastian Newrzela and Thomas Tousseyn and Xavier Sagaert and Maurilio Ponzoni and Fabio Facchetti and {De Wolf-Peeters}, Chris and Christian Steidl and Randy Gascoyne and Ralf K{\"u}ppers and Hansmann, {Martin Leo}",
year = "2013",
month = "11",
day = "11",
doi = "10.1371/journal.pone.0078812",
language = "English",
volume = "8",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "11",

}

TY - JOUR

T1 - Nodular lymphocyte predominant hodgkin lymphoma and T cell/histiocyte rich large B cell lymphoma - Endpoints of a spectrum of one disease?

AU - Hartmann, Sylvia

AU - Döring, Claudia

AU - Jakobus, Christina

AU - Rengstl, Benjamin

AU - Newrzela, Sebastian

AU - Tousseyn, Thomas

AU - Sagaert, Xavier

AU - Ponzoni, Maurilio

AU - Facchetti, Fabio

AU - De Wolf-Peeters, Chris

AU - Steidl, Christian

AU - Gascoyne, Randy

AU - Küppers, Ralf

AU - Hansmann, Martin Leo

PY - 2013/11/11

Y1 - 2013/11/11

N2 - In contrast to the commonly indolent clinical behavior of nodular lymphocyte predominant Hodgkin lymphoma (NLPHL), T cell/histiocyte rich large B cell lymphoma (THRLBCL) is frequently diagnosed in advanced clinical stages and has a poor prognosis. Besides the different clinical presentations of these lymphoma entities, there are variants of NLPHL with considerable histopathologic overlap compared to THRLBCL. Especially THRLBCL-like NLPHL, a diffuse form of NLPHL, often presents a histopathologic pattern similar to THRLBCL, suggesting a close relationship between both lymphoma entities. To corroborate this hypothesis, we performed gene expression profiling of microdissected tumor cells of NLPHL, THRLBCL-like NLPHL and THRLBCL. In unsupervised analyses, the lymphomas did not cluster according to their entity. Moreover, even in supervised analyses, very few consistently differentially expressed transcripts were found, and for these genes the extent of differential expression was only moderate. Hence, there are no clear and consistent differences in the gene expression of the tumor cells of NLPHL, THRLBCL-like NLPHL and THRLBCL. Based on the gene expression studies, we identified BAT3/BAG6, HIGD1A, and FAT10/UBD as immunohistochemical markers expressed in the tumor cells of all three lymphomas. Characterization of the tumor microenvironment for infiltrating T cells and histiocytes revealed significant differences in the cellular composition between typical NLPHL and THRLBCL cases. However, THRLBCL-like NLPHL presented a histopathologic pattern more related to THRLBCL than NLPHL. In conclusion, NLPHL and THRLBCL may represent a spectrum of the same disease. The different clinical behavior of these lymphomas may be strongly influenced by differences in the lymphoma microenvironment, possibly related to the immune status of the patient at the timepoint of diagnosis.

AB - In contrast to the commonly indolent clinical behavior of nodular lymphocyte predominant Hodgkin lymphoma (NLPHL), T cell/histiocyte rich large B cell lymphoma (THRLBCL) is frequently diagnosed in advanced clinical stages and has a poor prognosis. Besides the different clinical presentations of these lymphoma entities, there are variants of NLPHL with considerable histopathologic overlap compared to THRLBCL. Especially THRLBCL-like NLPHL, a diffuse form of NLPHL, often presents a histopathologic pattern similar to THRLBCL, suggesting a close relationship between both lymphoma entities. To corroborate this hypothesis, we performed gene expression profiling of microdissected tumor cells of NLPHL, THRLBCL-like NLPHL and THRLBCL. In unsupervised analyses, the lymphomas did not cluster according to their entity. Moreover, even in supervised analyses, very few consistently differentially expressed transcripts were found, and for these genes the extent of differential expression was only moderate. Hence, there are no clear and consistent differences in the gene expression of the tumor cells of NLPHL, THRLBCL-like NLPHL and THRLBCL. Based on the gene expression studies, we identified BAT3/BAG6, HIGD1A, and FAT10/UBD as immunohistochemical markers expressed in the tumor cells of all three lymphomas. Characterization of the tumor microenvironment for infiltrating T cells and histiocytes revealed significant differences in the cellular composition between typical NLPHL and THRLBCL cases. However, THRLBCL-like NLPHL presented a histopathologic pattern more related to THRLBCL than NLPHL. In conclusion, NLPHL and THRLBCL may represent a spectrum of the same disease. The different clinical behavior of these lymphomas may be strongly influenced by differences in the lymphoma microenvironment, possibly related to the immune status of the patient at the timepoint of diagnosis.

UR - http://www.scopus.com/inward/record.url?scp=84892910468&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892910468&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0078812

DO - 10.1371/journal.pone.0078812

M3 - Article

C2 - 24244368

AN - SCOPUS:84892910468

VL - 8

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 11

M1 - e78812

ER -